Cyteir Therapeutics Inc

NASDAQ CYT

Data sourced from

and

Download Data

Cyteir Therapeutics Inc Shares (Common, Diluted) 3 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023: 14.68%

Cyteir Therapeutics Inc Shares (Common, Diluted) 3 year CAGR is 14.68% for the Trailing 12 Months (TTM) ending September 30, 2023. Shares (Common, Diluted) represent the number of common shares outstanding, including potential dilution from stock options, convertible securities, or other instruments. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Cyteir Therapeutics Inc Shares (Common, Diluted) for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 35.33 M, a 0.76% change year over year.
Cyteir Therapeutics Inc Shares (Common, Diluted) for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 35.06 M, a 46.77% change year over year.
Cyteir Therapeutics Inc Shares (Common, Diluted) for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 23.89 M.

NASDAQ: CYT

Cyteir Therapeutics Inc

CEO	Mr. Joseph S. Zakrzewski
IPO Date	June 18, 2021
Location	United States
Headquarters	128 Spring Street, Lexington, MA, United States, 02421
Employees	46
Sector	Healthcare
Industry	Biotechnology

Description

Cyteir Therapeutics, Inc., a clinical-stage biotechnology company, develops and commercializes the oncology therapeutics. Its lead product CYT-0851, an oral investigational drug that inhibits monocarboxylate transporters that is in Phase I/II clinical trial for monotherapy in solid tumors and hematologic malignancies, as well as for combination therapy in solid tumors and hematologic malignancies. Cyteir Therapeutics, Inc. was incorporated in 2012 and is headquartered in Lexington, Massachusetts.

Key trends